

## COMPANY OVERVIEW

### Company Information

Company:	APONTIS PHARMA AG
Registered Office:	Alfred-Nobel-Str. 10, 40789 Monheim am Rhein, Germany
Phone number:	+49 2173 8955 4949
Webpage:	apontis-pharma.de
Contact mail:	info@apontis-pharma.de
Date of incorporation:	24 May 2018
Country of incorporation:	Germany
Financial year end:	31 December
Accounting standard:	HGB (German GAAP)
Consolidation obligation:	Yes
Executive Board:	Bruno Wohlschlegel (CEO) Thomas Milz (CPO)
Supervisory Board:	Dr. Matthias Wiedenfels (Chairman) Olaf Elbracht (Deputy Chairman) Dr. Edin Hadzic Christian Bettinger Dr. Anna Lisa Picciolo-Lehrke

Submitting Capital Market Partner: Hauck & Aufhäuser Privatbankiers AG

Advising Capital Market Partner: Hauck & Aufhäuser Privatbankiers AG

### Company Description

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. APONTIS PHARMA develops, promotes, and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS PHARMA has successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia, and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical regions. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target audience of approx. 25,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit [www.apontis-pharma.de](http://www.apontis-pharma.de).

## COMPANY OVERVIEW

### Relevant Trading Data

ISIN: DE000A3CMGM5  
 Stock exchange: XETRA and Frankfurt, Berlin, Dusseldorf, Munich, Tradegate  
 Designated Sponsor: Hauck & Aufhäuser Privatbankiers AG  
 Specialist: Wolfgang Steubing AG

### Relevant Asset Data

#### Stocks

Registered shares issued and outstanding: 8,500,000  
 Share capital: EUR 8,500,000.00  
 Shareholder structure:

<b>Name</b>	<b>in %</b>
The Paragon Fund II GmbH & Co. KG	37.0
Free Float	63.0
<b>Sum</b>	<b>100.00</b>